Theralase Technologies Inc. Stock
Stocks
TLT
CA88337V1004
Advanced Medical Equipment & Technology
OTC Markets Traded|
Market Closed -
Toronto S.E.
00:41:42 04/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.1800 CAD | -7.69% |
|
-10.00% | +9.09% |
| 10-26 | Theralase® Technologies Inc. Provides Bladder Cancer Clinical Study Update and Oncology Pipeline Expansion | CI |
| 09-15 | Theralase Technologies Commences GLP Toxicology Analysis of Rutherrin | CI |
| Market Cap | 55.89M 39.93M 35.67M 32.77M 29.76M 3.78B 57.29M 391M 157M 2B 150M 147M 6.33B | P/E 2026 * |
-18x | P/E 2027 * | 9x |
|---|---|---|---|---|---|
| Enterprise Value | 55.89M 39.93M 35.67M 32.77M 29.76M 3.78B 57.29M 391M 157M 2B 150M 147M 6.33B | EV / Sales 2026 * |
71.1x | EV / Sales 2027 * | 1.65x |
| Free-Float |
79.6% | Yield 2026 * |
-
| Yield 2027 * | - |
Toronto S.E.CAD
| Markets | Quality | ||
|---|---|---|---|
Toronto S.E.
| TLT | Delayed | |
OTC Markets
| TLTFF | Delayed | |
Deutsche Boerse AG
| TTX | Delayed | |
Börse Stuttgart
| TTX | Delayed |
Last Transcript: Theralase Technologies Inc.
| 1 day | -7.69% | ||
| 1 week | -10.00% | ||
| 1 month | +2.86% | ||
| 3 months | -36.84% | ||
| 6 months | -40.98% | ||
| Current year | +9.09% |
| 1 week | 0.18 | 0.2 | |
| 1 month | 0.18 | 0.25 | |
| Current year | 0.16 | 0.41 | |
| 1 year | 0.14 | 0.41 | |
| 3 years | 0.14 | 0.41 | |
| 5 years | 0.14 | 0.48 | |
| 10 years | 0.12 | 0.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 29/06/2023 | |
Kristina Hachey
DFI | Director of Finance/CFO | - | 27/06/2019 |
Arkady Mandel
CEO | Chief Executive Officer | - | 15/11/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | - | |
Kristina Hachey
BRD | Director/Board Member | - | 27/06/2019 |
Randy Bruder
BRD | Director/Board Member | - | 01/01/2008 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/08/26 | Option | Director | 3,360 | 0.0011% | ||
| 27/08/26 | Buy | Chief Executive Officer | 42,000 | 0.0142% | ||
| 24/08/26 | Option | Chief Financial Officer | 29,000 | 0.0098% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -7.69% | -10.00% | -14.29% | -7.69% | 43.33M | ||
| +2.30% | +1.96% | +23.08% | +56.03% | 253B | ||
| +0.94% | -1.23% | +6.84% | +19.24% | 160B | ||
| +0.89% | -2.41% | -17.51% | +58.61% | 151B | ||
| -1.85% | -4.56% | -56.81% | -17.17% | 64.23B | ||
| -0.12% | +2.51% | -10.75% | -8.53% | 54.11B | ||
| +2.07% | +5.11% | +15.45% | +45.26% | 53.76B | ||
| -1.23% | -4.70% | +4.12% | +59.66% | 49.71B | ||
| +2.02% | -0.28% | +19.88% | +67.95% | 48.49B | ||
| +2.31% | +0.86% | +31.55% | +87.40% | 44.17B | ||
| Average | -0.02% | -0.94% | +0.16% | +36.08% | 87.93B | |
| Weighted average by Cap. | +1.14% | -0.75% | +3.92% | +42.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 786K 562K 502K 461K 419K 53.2M 806K 5.5M 2.21M 28.08M 2.11M 2.06M 88.99M | 33.89M 24.21M 21.63M 19.87M 18.05M 2.29B 34.74M 237M 95.41M 1.21B 90.88M 88.94M 3.84B |
| Net income | -4.12M -2.95M -2.63M -2.42M -2.2M -279M -4.23M -28.86M -11.61M -147M -11.06M -10.82M -467M | 6.9M 4.93M 4.4M 4.05M 3.67M 467M 7.07M 48.3M 19.43M 247M 18.51M 18.11M 781M |
| Net Debt | - | - |
Employees
20
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/11/26 | CA$0.1800 | -7.69% | 40,902 |
| 02/11/26 | CA$0.1950 | +8.33% | 1,285 |
| 30/10/26 | CA$0.1800 | -10.00% | 139,043 |
| 29/10/26 | CA$0.2000 | 0.00% | 23,500 |
| 28/10/26 | CA$0.2000 | 0.00% | 39,890 |
Sell
Buy

Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1800CAD
Average target price
0.7000CAD
Spread / Average Target
+288.89%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TLT Stock
Select your edition
All financial news and data tailored to specific country editions

















